Printed From:

Bibliografía

2.
Benjamin EJ, Wolf PA, D'Agostino RB, Silbershatz H, Kannel WB, Levy D. Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. Circulation 1998; 98: 946-52.
3.
Bruggenjurgen B, Rossnagel K, Roll S, et al. The impact of atrial fibrillation on the cost of stroke: the berlin acute stroke study. Value Health 2007; 10: 137-43.
4.
Cappato R, Calkins H, Chen SA, et al. Worldwide survey on the methods, efficacy, and safety of catheter ablation for human atrial fibrillation. Circulation 2005; 111: 1100-5.
5.
Du X, Ninomiya T, de Galan B, et al. Risks of cardiovascular events and effects of routine blood pressure lowering among patients with type 2 diabetes and atrial fibrillation: results of the ADVANCE study. Eur Heart J 2009; 30: 1128-35.
6.
Foerch C, Misselwitz B, Sitzer M, Steinmetz H, Neumann-Haefelin T. The projected burden of stroke in the german federal state of hesse up to the year 2050. Dtsch Arztebl Int 2008; 105: 467-73.
8.
Go AS, Hylek EM, Phillips KA, et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. Jama 2001; 285: 2370-5.
10.
Kirchhof P, Auricchio A, Bax J, et al. Outcome parameters for trials in atrial fibrillation: executive summary. Eur Heart J 2007; 28: 2803-17.
11.
Kompetenznetz Vorhofflimmern. Vernetzt forschen – schneller umsetzen. Zum Wohle des Patienten. Kompetenznetz Schlaganfall. (http://www.kompetenznetz-schlaganfall.de/netz.0.html), 2009.
12.
Lafuente-Lafuente C, Mouly S, Longas-Tejero MA, Mahe I, Bergmann JF. Antiarrhythmic drugs for maintaining sinus rhythm after cardioversion of atrial fibrillation: a systematic review of randomized controlled trials. Arch Intern Med 2006; 166: 719-28.
13.
McBride D, Mattenklotz AM, Willich SN, Bruggenjurgen B. The Costs of Care in Atrial Fibrillation and the Effect of Treatment Modalities in Germany. Value Health 2008.
14.
Nieuwlaat R, Capucci A, Camm AJ, et al. Atrial fibrillation management: a prospective survey in ESC member countries: the Euro Heart Survey on Atrial Fibrillation. Eur Heart J 2005; 26: 2422-34.
15.
Ouyang F, Bansch D, Ernst S, et al. Complete isolation of left atrium surrounding the pulmonary veins: new insights from the double-Lasso technique in paroxysmal atrial fibrillation. Circulation 2004; 110: 2090-6.
16.
Stewart S, Hart CL, Hole DJ, McMurray JJ. A population-based study of the long-term risks associated with atrial fibrillation: 20-year follow-up of the Renfrew/Paisley study. Am J Med 2002; 113: 359-64.
17.
Vidaillet H, Granada JF, Chyou PH, et al. A population-based study of mortality among patients with atrial fibrillation or flutter. Am J Med 2002; 113: 365-70.
18.
Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke 1991; 22: 983-8.

  1. Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. The Cardiac Arrhythmia Suppression Trial (CAST) Investigators. N Engl J Med 1989; 321: 406-12.
  2. Benjamin EJ, Wolf PA, D'Agostino RB, Silbershatz H, Kannel WB, Levy D. Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. Circulation 1998; 98: 946-52.
  3. Bruggenjurgen B, Rossnagel K, Roll S, et al. The impact of atrial fibrillation on the cost of stroke: the berlin acute stroke study. Value Health 2007; 10: 137-43.
  4. Cappato R, Calkins H, Chen SA, et al. Worldwide survey on the methods, efficacy, and safety of catheter ablation for human atrial fibrillation. Circulation 2005; 111: 1100-5.
  5. Du X, Ninomiya T, de Galan B, et al. Risks of cardiovascular events and effects of routine blood pressure lowering among patients with type 2 diabetes and atrial fibrillation: results of the ADVANCE study. Eur Heart J 2009; 30: 1128-35.
  6. Foerch C, Misselwitz B, Sitzer M, Steinmetz H, Neumann-Haefelin T. The projected burden of stroke in the german federal state of hesse up to the year 2050. Dtsch Arztebl Int 2008; 105: 467-73.
  7. Camm J, et al. Guidelines for the management of atrial fibrillation. The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). European Heart Journal (2010) 31, 2369–2429.
  8. Go AS, Hylek EM, Phillips KA, et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. Jama 2001; 285: 2370-5.
  9. Hohnloser SH, Crijns HJ, van Eickels M, et al. Effect of dronedarone on cardiovascular events in atrial fibrillation. N Engl J Med 2009; 360: 668-78.
  10. Kirchhof P, Auricchio A, Bax J, et al. Outcome parameters for trials in atrial fibrillation: executive summary. Eur Heart J 2007; 28: 2803-17.
  11. Kompetenznetz Vorhofflimmern. Vernetzt forschen – schneller umsetzen. Zum Wohle des Patienten. Kompetenznetz Schlaganfall. (http://www.kompetenznetz-schlaganfall.de/netz.0.html), 2009.
  12. Lafuente-Lafuente C, Mouly S, Longas-Tejero MA, Mahe I, Bergmann JF. Antiarrhythmic drugs for maintaining sinus rhythm after cardioversion of atrial fibrillation: a systematic review of randomized controlled trials. Arch Intern Med 2006; 166: 719-28.
  13. McBride D, Mattenklotz AM, Willich SN, Bruggenjurgen B. The Costs of Care in Atrial Fibrillation and the Effect of Treatment Modalities in Germany. Value Health 2008.
  14. Nieuwlaat R, Capucci A, Camm AJ, et al. Atrial fibrillation management: a prospective survey in ESC member countries: the Euro Heart Survey on Atrial Fibrillation. Eur Heart J 2005; 26: 2422-34.
  15. Ouyang F, Bansch D, Ernst S, et al. Complete isolation of left atrium surrounding the pulmonary veins: new insights from the double-Lasso technique in paroxysmal atrial fibrillation. Circulation 2004; 110: 2090-6.
  16. Stewart S, Hart CL, Hole DJ, McMurray JJ. A population-based study of the long-term risks associated with atrial fibrillation: 20-year follow-up of the Renfrew/Paisley study. Am J Med 2002; 113: 359-64.
  17. Vidaillet H, Granada JF, Chyou PH, et al. A population-based study of mortality among patients with atrial fibrillation or flutter. Am J Med 2002; 113: 365-70.
  18. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke 1991; 22: 983-8.

Área para Profesionales

Perfil